A 58-year-old man with Child-Pugh class B cirrhosis secondary to chronic hepatitis B presents with right upper quadrant pain and weight loss. Multiphasic CT imaging shows a 4 cm solitary lesion in the right lobe with arterial phase hyperenhancement and venous phase washout. The structure marked **B** in the diagram demonstrates vascular invasion of the portal vein. Which of the following is the most appropriate next step in management for this patient?
A. Transarterial chemoembolization (TACE)
B. Sorafenib monotherapy as first-line systemic therapy
C. Liver transplantation per Milan criteria
D. Hepatic resection with curative intent
Explanation
Why Transarterial chemoembolization (TACE) is right
The presence of vascular (portal vein) invasion in HCC, as shown at structure B, is a hallmark feature that excludes the patient from curative-intent surgical resection and transplantation. According to BCLC staging and AASLD guidelines, vascular invasion represents advanced-stage disease (BCLC-C). While the tumor is solitary and <5 cm, the portal vein invasion violates the Milan criteria (which explicitly exclude vascular invasion) and renders hepatic resection inappropriate due to high recurrence risk. TACE is the standard locoregional therapy for intermediate-stage HCC and remains a reasonable option for select advanced cases with preserved performance status and liver function (Child-Pugh B). It delivers chemotherapy directly via the hepatic artery—the primary blood supply to HCC—while occluding the tumor vasculature.
Why each distractor is wrong
Liver transplantation per Milan criteria: Milan criteria explicitly exclude patients with vascular invasion. Although the tumor is solitary and <5 cm, the portal vein invasion documented at structure B makes this patient ineligible for transplantation, which is reserved for HCC without vascular invasion.
Hepatic resection with curative intent: Vascular invasion is a contraindication to surgical resection due to extremely high recurrence and mortality rates. While the patient has a solitary lesion, the portal vein invasion at structure B precludes curative resection; resection would be palliative at best and is not the standard approach.
Sorafenib monotherapy as first-line systemic therapy: Although sorafenib is an approved option for advanced HCC, it is not the first-line systemic agent. Current evidence (IMbrave150 trial, AASLD 2023) favors atezolizumab + bevacizumab as first-line for advanced disease. Moreover, locoregional therapy (TACE) is preferred over systemic therapy alone in this setting given the patient's preserved performance status and liver function.
High-YieldNEET PG
Vascular invasion in HCC excludes transplantation and resection; it defines BCLC-C (advanced) disease and mandates locoregional or systemic therapy depending on performance status and liver reserve.
